DiaMedica Initiates New Type 1 Diabetes Program


DiaMedica Inc., a Canadian biopharmaceutical company focused on developing novel treatments for diabetes and neurological disorders, announced the initiation of a type 1 diabetes program following the acquisition of Sanomune. The initiation of this program is based on encouraging preclinical results with DM-99, a naturally occurring protein that the company has previously shown to have clinical efficacy for type 2 diabetes. The initial results from this study, on animals, showed that DM-99 was able to reduce fasting blood glucose, an indication that new beta cells may be created or that existing beta cells are being protected.

Leave a Reply

Notify of
Copyright © 2009-2018 Diabetes Media Foundation, All Rights Reserved.
ASweetLife™ is a trademark of the Diabetes Media Foundation, All Rights Reserved.